Skip to main content
. 2019 Apr 17;176(1):27–36. doi: 10.1007/s10549-019-05233-9

Table 3.

Overview of results of the included articles studying progesterone receptor (PR) load in 14,161 patients

References Level of evidence and design Number of patients Outcome measure Median FU (years) Significant association
Bartlett 2011 [18] 2b, RCT 4325 DFS 5 Yes
Dowsett 2008 [22] 1b, RCT 1856 DFS 5.7 Yes
Prat 2013 [29] 4, cohort 701 DRFS 12.5 Marginally
Campbell 2016 [19] 2b, cohort 503 DFS 5.7 No
Chae 2011 [20] 2c, cohort 171 DFS 4.3 No
Chapman 2013 [21] 1b, RCT 345 DFS 9.7 No
Esslimani-Sahla 2004 [23] 3b, case–control 50 Recurrence 5 No
Harigopal 2010 [9] 2b, RCT 1715 DFS 7.2 No
Liu 2010 [33] 2b, cohort 4046 BCSS 10 No
Nordenskjold 2016 [34] 2b, RCT 449 Recurrence 18 No

In case of statistically significant associations, a higher PR load is associated with better clinical outcome. Level of evidence, according to the Oxford Centre of Evidence-Based Medicine [16]

FU Follow-up, DFS Disease-free survival, DRFS Distant recurrence-free survival, BCSS Breast cancer-specific survival